EUVIMEDEUVIMED entdecken
Crossref

Advances in immunotherapy and its role in enhancing survival rates for patients with metastatic melanoma

Elmira Mainazarova, Taasilkan Zhumabaeva, Kanybek Matsakov, Gulnara Inamzhanova, Samidin Begaly uulu

Journal of Human Biology and Clinical Medicine · 2026

DOI: 10.63621/jhbcm/3.2026.66 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Human Biology and Clinical Medicine, 2026. Verfasst von Elmira Mainazarova und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study was to evaluate the impact of advanced immunotherapy methods on the clinical outcomes and survival of patients with metastatic melanoma, and to determine the effectiveness of individual therapeutic strategies in a Polish setting. The study was conducted at the Warsaw Oncology Centre from June 1, 2023 to June 1, 2025 and included 128 patients with a confirmed diagnosis of metastatic melanoma. The study was conducted using prospective cohort follow-up, clinical and epidemiological analysis, and standardised assessment of tumour response with control for overall survival over 12 months. During regular clinical follow-up, it was found that the effectiveness of immunotherapy significantly depended on the chosen therapeutic strategy. In the monotherapy group, partial remission was observed in 38.7% of patients, while disease stabilisation and progression were recorded in 30.6% of patients in each category. In the combined immunotherapy group, complete or partial remission was achieved in 66.7% of patients (complete remission – in 13.6%), disease stabilisation was observed in 22.7%, and progression – only in 10.6% of cases. The average overall survival rate was 12.5 months in the monotherapy group and 19.2 months in the combination therapy group (p < 0.01), which indicated a significant advantage of the combined approach. Progression-free survival rates were also higher with combination treatment (13.1 months vs. 7.4 months). Treatment was characterised by an acceptable safety profile: in the monotherapy group, severe immune-mediated side effects were not recorded, while in combination therapy they occurred in 12.1% of patients and included hepatitis, colitis, and endocrine disorders, but in all cases they were controlled after temporary discontinuation of treatment and administration of systemic corticosteroids. The results confirmed the high effectiveness of current immunotherapy strategies in improving the survival and quality of life in patients with metastatic melanoma

Zitieren

APA

Mainazarova, E., Zhumabaeva, T., Matsakov, K., Inamzhanova, G., & uulu, S. B. (2026). Advances in immunotherapy and its role in enhancing survival rates for patients with metastatic melanoma. Journal of Human Biology and Clinical Medicine. https://doi.org/10.63621/jhbcm/3.2026.66

Vancouver

Mainazarova E, Zhumabaeva T, Matsakov K, Inamzhanova G, uulu SB. Advances in immunotherapy and its role in enhancing survival rates for patients with metastatic melanoma. Journal of Human Biology and Clinical Medicine. 2026. doi:10.63621/jhbcm/3.2026.66

BibTeX
@article{Mainazarova2026,
  author = {Mainazarova, Elmira and Zhumabaeva, Taasilkan and Matsakov, Kanybek and Inamzhanova, Gulnara and uulu, Samidin Begaly},
  title = {Advances in immunotherapy and its role in enhancing survival rates for patients with metastatic melanoma},
  journal = {Journal of Human Biology and Clinical Medicine},
  year = {2026},
  doi = {10.63621/jhbcm/3.2026.66}
}
Kostenlos starten →